共 286 条
[1]
Siegel RL(2018)Cancer statistics, 2018 CA Cancer J Clin 68 7-30
[2]
Miller KD(2010)The management of resectable and unresectable liver metastases from colorectal cancer Curr Opin Oncol 22 364-373
[3]
Jemal A(2013)Colorectal liver metastases J Gastrointest Surg 17 195-201
[4]
Kemeny N(2015)A randomized phase II clinical study of combining panitumumab and bevacizumab, plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) compared with FOLFIRI alone as second-line treatment for patients with metastatic colorectal cancer and KRAS mutation OncoTargets Therapy 8 1061-1068
[5]
Tzeng CW(2015)A multi-center randomized phase II clinical study of bevacizumab plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) compared with FOLFIRI alone as second-line treatment for Chinese patients with metastatic colorectal cancer Med Oncol 32 325-1075
[6]
Aloia TA(2017)The efficacy and safety of CapeOX plus bevacizumab therapy followed by capecitabine plus bevacizumab maintenance therapy in patients with metastatic colorectal cancer: a multi-center, single-arm, phase II study (CCOG-0902) BMC Cancer 17 243-S314
[7]
Liu Y(2016)Cost-minimization analysis of adjuvant chemotherapy regimens given to patients with colorectal cancer in Japan J Pharm Health Care Sci 2 1065-356
[8]
Luan L(2014)FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial Lancet Oncol 15 108-417
[9]
Wang X(2014)A phase IotaI study of five peptides combination with oxaliplatin-based chemotherapy as a first-line therapy for advanced colorectal cancer (FXV study) J Transl Med 12 S312-284
[10]
Cao R(2011)Current standards and new trends in the primary treatment of colorectal cancer Eur J Cancer 47 338-347